Low-molecular-weight heparins in the management of unstable angina

Haemostasis

Volumn 30, Issue SUPPL. 2, 2000, Pages 158-167

  Agnelli, Giancarlo ^a   Sonaglia, Francesco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Aspirin; Low molecular weight heparin; Unfractionated heparin; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; DRUG SAFETY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVASCULARIZATION; UNSTABLE ANGINA PECTORIS;

EID: 0034461216     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054184     Document Type: Conference Paper

References (19)

1. Production and chemical processing of low molecular weight heparins
2. Structural characterization of low molecular weight heparins
3. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins
4. Human pharmacokinetics of low molecular weight heparins
5. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial
6. Antithrombotic agents in coronary artery disease
7. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
8. Low-molecular-weight heparin during instability in coronary artery disease
9. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
10. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
11. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE study
12. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
13. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S (FRAXiparine in Ischaemic Syndromes)
14. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
15. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
16. Assessment of the treatment efficacy of enoxaparin for unstable angina/non-Q wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
17. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
18. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users. Primary end points analysis from the ATACS trials
19. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease